Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease

Pilot Study for Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02249715

Enrollment

Registered

2014-09-26

Start date

2014-11-30

Completion date

Unknown

Last updated

2014-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson

Keywords

Parkinson, TMS, BNA

Brief summary

* To characterize physiological biomarkers of positive response to rDTMS using EEG and functional MRI (fMRI) in patients with PD. * To develop a set-up and algorithm for neurophysiological monitoring for PD patients using EEG and fMRI in patients treated by rDTMS. * To integrate rDTMS stimulation with monitoring techniques with the ultimate goal of providing closed-loop feedback where monitoring informs the stimulation

Detailed description

PD Patients aged 40 years or older, diagnosed as idiopathic PD according to the UK Brain Bank criteria will be treated by an established rDTMS protocol will be monitored before, during and after rDTMS using quantitative EEG and brain network analysis and fMRI while performing a series of cognitive and motor tasks.

Interventions

DEVICEBrainsway Multiway deep TMS device (two channels)

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Idiopathic PD patients aged 40-75 years; 2. Hoehn and Yahr stages II to IV 3. Patients on stable antiparkinsonian therapy for 1 month 4. Right hand dominance with right afflicted side.

Exclusion criteria

1. Participation in current clinical study or clinical study within 30 days prior to this study. 2. Subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to drugs, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or other degenerative disease) 3. Patients with significant psychiatric symptoms or history. 4. Patients with psychotic symptoms or active depressive symptoms 5. Treatment with neuroleptics. 6. Beck depression inventory (BDI) score \<14 7. Mini Mental status examination (MMSE) score \<25 8. History of migraine or frequent or severe headaches. 9. Significant sensory deficits, e.g., deafness or blindness History of head injury or neurosurgical interventions. 10. Subjects who have concomitant epilepsy, a history of seizure/s, heat convulsions or history of epilepsy in first degree relative. 11. History of any metal in the head (outside the mouth). 12. The presence of cochlear implants 13. Known history of any metallic particles in the eye, implanted cardiac pacemaker, implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps. 14. Subjects with an unstable medical disorder. 15. Current drug abuse (including Cannabis) or alcoholism. 16. Pregnancy or not using a reliable method of birth control. 17. Patients with severe tremor or dyskinesia

Design outcomes

Primary

Measure	Time frame
Unified Parkinson's Disease Rating Scale (UPDRS)	3 month

Contacts

Primary ContactOren Cohen, M.D

Oren.Cohen@sheba.health.gov.il972-3-5305296

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026